The Cancer Letter

Inside information on cancer research and drug development

Regulatory News

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors

Problem: “Breast density is in the eye of the mammographer”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Collage art of mammograms of dense breastsIllustrator: Cyrus Finegan

While breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Table of Contents

YOU MAY BE INTERESTED IN

ACS report: Cancer mortality continues to drop despite rising incidence in women

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
By Yiqing Wang
Clinical Roundup

Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study shows

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 
Clinical Roundup

AI improves breast cancer diagnosis

Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.
Byline
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account